-
PP 2 (AG 1879): Src Kinase Evidence
2026-08-27
PP 2, also called AG 1879, is a selective Src-family kinase inhibitor with nanomolar reported potency against Lck and Fyn. Its research value spans inhibition of Src-mediated cell proliferation, glioma cell invasion inhibition, T cell signal transduction inhibition, and mechanistic vascular studies, but its selectivity has defined limits.
-
NIAGEN and NAD+ Logic in iPSC-RGC Models
2026-08-26
A translational framework for evaluating Nicotinamide Riboside Chloride (NIAGEN) in stem cell-derived retinal ganglion cell systems, connecting NAD+ biology with reproducible differentiation, metabolic dysfunction research, and neurodegenerative disease modeling.
-
Palmitic acid: Protocol and QC Guide
2026-08-26
Palmitic acid (SKU N2456) provides a characterized saturated long-chain fatty acid for controlled studies of lipid metabolism, inflammation, insulin signaling, and protein palmitoylation. It is intended for non-aqueous preparation with prompt use, not for water-based workflows or long-term storage of solutions.
-
N4-Acetylcytidine: From Molecule to RNA Meaning
2026-08-25
N4-Acetylcytidine is more than an RNA modification standard: it is a defined probe for separating free-nucleoside metabolism from RNA-bound ac4C biology. This guide translates recent ASCH-domain structural findings into stronger assay controls, interpretation, and experimental design.
-
Reserpine (N1867): Practical Lab Workflow
2026-08-25
Reserpine (SKU N1867) provides a defined research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and related neuropharmacology workflows. This guide focuses on identity confirmation, DMSO preparation, storage, QC, and troubleshooting; it does not establish clinical efficacy, diagnostic use, or assay-specific dosing.
-
CB-5083: Selective p97 Inhibitor for Oncology Research
2026-08-24
CB-5083 is an orally bioavailable p97 inhibitor that competes with ATP at the second p97 ATPase domain. Product-reported data connect p97 inhibition with polyubiquitinated-protein accumulation, unfolded protein response activation, cancer cell apoptosis induction, and tumor growth inhibition in xenograft models.
-
HyperFluor 488 Goat Anti-Mouse IgG Guide
2026-08-24
HyperFluor 488 Goat Anti-Mouse IgG is a fluorescently labeled secondary antibody for detecting mouse IgG in immunofluorescence, flow cytometry, and western blot workflows. Its affinity-purified goat polyclonal format recognizes mouse IgG heavy and light chains, while documented concentration and storage conditions support controlled assay planning.
-
Betaine hydrochloride for inflammation-linked assays
2026-08-23
Betaine hydrochloride provides a defined, water-compatible variable for metabolic enzyme research, protease assay development, and pathway-oriented molecular workflows. This article translates an inflammation-linked esophageal cancer study into practical assay controls without presenting betaine hydrochloride as an untested anticancer treatment.
-
Intravesical p21 mRNA-LNPs in Bladder Cancer
2026-08-22
This FASEB Journal study develops a nonviral intravesical delivery strategy using chemically modified p21 mRNA encapsulated in lipid nanoparticles to restore tumor-suppressor activity in bladder cancer. The approach produced bladder-localized expression, inhibited tumor growth in an orthotopic mouse model, and offers a mechanistically supported framework for localized mRNA delivery.
-
Lovastatin as a Translational Probe of Cell Fate
2026-08-22
Lovastatin is more than a cholesterol biosynthesis inhibitor: it is a pathway-level probe for connecting mevalonate metabolism with proliferation, apoptosis, tissue remodeling, and macrophage clearance. This article outlines how translational researchers can use it rigorously while drawing a carefully bounded conceptual bridge to KNUCKLES-controlled plant meristem determinacy.
-
Nanoparticle mRNA Delivery to Reverse Trastuzumab Resistance
2026-08-21
Dong and colleagues developed tumor microenvironment pH-responsive nanoparticles for systemic delivery of PTEN mRNA to HER2-positive breast cancer models with trastuzumab resistance. The study links tumor-selective nanoparticle activation, restored PTEN expression, and PI3K/Akt signaling pathway inhibition to renewed trastuzumab sensitivity, offering a mechanistic framework for resistance-reversal research.
-
Faropenem Sodium: Research Workflows and AMR Insights
2026-08-20
Translate Faropenem sodium’s broad penem activity into reproducible MIC, anaerobe, and resistance-selection experiments. This practical guide separates assay potency from stewardship interpretation while providing fresh-solution handling, protocol parameters, comparison strategies, and troubleshooting guidance.
-
TSPAN18–STIM1 Drives Prostate Cancer Bone Metastasis
2026-08-20
Zhou et al. identify TSPAN18 as a stabilizing binding partner of STIM1 that prevents TRIM32-mediated ubiquitination and degradation. The resulting increase in store-operated calcium entry promotes prostate cancer cell migration, invasion, and bone metastasis, providing a mechanistic framework for studying calcium-dependent metastatic progression.
-
Pol II Degradation and Transcription-Independent Cell Death
2026-08-19
The preprint proposes that RNA polymerase II degradation can activate cell death through a mechanism that is not explained solely by the accompanying loss of transcription. Its experimental logic highlights why cancer studies should measure polymerase abundance, transcriptional output, proliferation, and cell death as related but distinct endpoints.
-
Metabolic Sensitization of Ferroptosis and Cuproptosis
2026-08-19
The reference study introduces SCu/L, a copper–tannic acid network/liposome system that combines copper delivery with STF-31-mediated metabolic intervention. By suppressing glycolysis and compensatory NAD+ metabolism, the platform reduces antioxidant and energy reserves, limits copper efflux, and strengthens ferroptosis, cuproptosis, and antitumor immune responses. Its main practical implication is that regulated cell death can be amplified by targeting shared metabolic dependencies rather than by increasing metal delivery alone.